In the last week, the Indian market has stayed flat, but it is up 44% over the past year with earnings forecast to grow by 17% annually. In this thriving environment, identifying stocks with strong growth potential and solid fundamentals can be especially rewarding.
Top 10 Undiscovered Gems With Strong Fundamentals In India
| Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
|---|---|---|---|---|
| Shree Digvijay Cement | 0.01% | 13.97% | 16.37% | ★★★★★★ |
| All E Technologies | NA | 40.78% | 31.63% | ★★★★★★ |
| Bharat Rasayan | 8.15% | 0.10% | -7.93% | ★★★★★★ |
| ELANTAS Beck India | NA | 14.89% | 24.83% | ★★★★★★ |
| Om Infra | 13.99% | 43.36% | 27.66% | ★★★★★☆ |
| Network People Services Technologies | 0.24% | 81.82% | 86.35% | ★★★★★☆ |
| Nibe | 39.26% | 80.75% | 84.69% | ★★★★★☆ |
| KP Green Engineering | 13.73% | 47.44% | 61.28% | ★★★★★☆ |
| Vasa Denticity | 0.11% | 38.37% | 48.77% | ★★★★☆☆ |
| Rir Power Electronics | 54.23% | 16.42% | 34.78% | ★★★★☆☆ |
Let's dive into some prime choices out of from the screener.
Action Construction Equipment (NSEI:ACE)
Simply Wall St Value Rating: ★★★★★★
Overview: Action Construction Equipment Limited manufactures and sells material handling and construction equipment primarily in India, with a market cap of ₹166.42 billion.
Operations: ACE generates revenue primarily from its material handling and construction equipment segments, with additional income from agriculture equipment amounting to ₹2.05 billion.
Action Construction Equipment (ACE) has shown remarkable growth, with earnings surging 76.2% in the past year, outpacing the Machinery industry's 25.1%. The company boasts a debt-to-equity ratio that has improved from 18.5% to 0.4% over five years and holds more cash than its total debt. Recent wins include a significant order from the Ministry of Defence for specialized forklifts and cranes, reflecting strong momentum under India's Make in India initiative.
Maharashtra Scooters (NSEI:MAHSCOOTER)
Simply Wall St Value Rating: ★★★★★☆
Overview: Maharashtra Scooters Ltd. manufactures and sells pressure die casting dies, jigs, fixtures, and die casting components primarily for the two and three-wheeler industry in India, with a market cap of ₹139.39 billion.
Operations: Maharashtra Scooters Ltd. generates revenue primarily through investments (₹2.14 billion) and manufacturing activities (₹108.10 million). The company's financial performance is influenced by these two main revenue streams, with investments contributing the majority of the income.
Maharashtra Scooters, a debt-free company, has seen its earnings grow at an annual rate of 19.3% over the past five years. Despite lagging behind the Capital Markets industry's 63.2% growth last year with only 6.6%, it remains profitable and free cash flow positive with INR 2254.62 million as of September 2023. Recent board changes include the resignation of Anish Amin and new appointment of Jasmine Chaney, while dividends were declared at INR 110 per share for FY2025 ending March.
- Click to explore a detailed breakdown of our findings in Maharashtra Scooters' health report.
Assess Maharashtra Scooters' past performance with our detailed historical performance reports.
Marksans Pharma (NSEI:MARKSANS)
Simply Wall St Value Rating: ★★★★★★
Overview: Marksans Pharma Limited, with a market cap of ₹144.26 billion, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations across various international markets including the United States, North America, Europe, the United Kingdom, Australia, and New Zealand.
Operations: Marksans Pharma generates revenue primarily from its pharmaceutical formulations segment, amounting to ₹22.68 billion. The company operates in various international markets including the United States, North America, Europe, the United Kingdom, Australia, and New Zealand.
Marksans Pharma has demonstrated robust financial health with a debt to equity ratio improving from 19.9% to 11.7% over the past five years, and earnings growth of 21.7% last year outpacing the industry average of 19.2%. The company’s interest payments are well covered by EBIT at 32 times coverage, reflecting strong operational efficiency. Recent developments include a successful USFDA inspection closure and plans for M&A activities aimed at expanding into the European market, indicating strategic growth initiatives ahead.
- Click here to discover the nuances of Marksans Pharma with our detailed analytical health report.
Explore historical data to track Marksans Pharma's performance over time in our Past section.
Make It Happen
- Explore the 476 names from our Indian Undiscovered Gems With Strong Fundamentals screener here.
- Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
- Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Curious About Other Options?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NSEI:MARKSANS
Marksans Pharma
Engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally.
Flawless balance sheet with solid track record.
